Group One Trading
BBIO icon

Group One Trading’s BridgeBio Pharma BBIO Stock Holding History

Group One Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,537
Closed -$2.2M – 8135
2025
Q3 		$1.74M Buy
33,537
+2,788
+9% +$136K ﹤0.01% 2450
2025
Q2 		$1.33M Buy
30,749
+17,912
+140% +$651K ﹤0.01% 2502
2025
Q1 		$444K Sell
12,837
-220,300
-94% -$7.43M ﹤0.01% 3221
2024
Q4 		$6.4M Buy
233,137
+108,235
+87% +$2.8M 0.01% 986
2024
Q3 		$3.18M Buy
+124,902
New +$3.28M 0.01% 1367
2023
Q4 		– Sell
-48,540
Closed -$1.46M – 7378
2023
Q3 		$1.28M Sell
48,540
-58,291
-55% -$1.65M ﹤0.01% 2025
2023
Q2 		$1.84M Sell
106,831
-12,902
-11% -$194K 0.01% 1782
2023
Q1 		$1.99M Buy
+119,733
New +$1.4M 0.01% 1534
2022
Q3 		– Sell
-83,858
Closed -$871K – 7540
2022
Q2 		$761K Buy
83,858
+54,883
+189% +$459K ﹤0.01% 3010
2022
Q1 		$294K Sell
28,975
-78,101
-73% -$802K ﹤0.01% 4390
2021
Q4 		$1.79M Buy
+107,076
New +$4.53M ﹤0.01% 2730

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Group One Trading's BBIO Position: Q4 2025 in Review

Group One Trading sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 33,537 shares — an estimated $2.2M sold.

Group One Trading first reported a position in BBIO in Q4 2021 and held it in 11 quarters. The position peaked at $6.4M in Q4 2024. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Group One Trading reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 33,537 BridgeBio Pharma shares in Q4 2025, an estimated $2.2M.
  • Group One Trading first reported a position in BridgeBio Pharma in Q4 2021 and held it in 11 quarters.
  • Group One Trading's BridgeBio Pharma position peaked at $6.4M in Q4 2024.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.